1. Abhold R.H., Sullivan M.J., Wright J.W., Harding J.W., Binding, degradation and pressor activity of angiotensins II and III after aminopeptidase inhibition with amastatin and bestatin.J Pharmacol Exp Ther, 1987, 242, 957–962.
2. Allen A.M., Paxinos G., Song K.F., Mendelsohn F.A.O., Localization of angiotensin receptor binding sites in the rat brain.InBjörklund A., Hökfelt T., Kuhar M.J. (Eds.),Handbook of Chemical Neuroanatomy, 1992, Elsevier, Amsterdam, vol. 11, pp. 1–37.
3. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMA, 2002, 288, 2981–2997.
4. Averill D.B., Matsumura K., Ganten D., Ferrario C.M., Role of area postrema in transgene hypertension.Hypertension, 1996, 27, 591–597.
5. Balavoine F., Azizi M., Bergerot D., De Mota N., Patouret R., Roques B., Llorens-Cortès C., Randomised, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Study of QGC001, a Centrally Acting Aminopeptidase A Inhibitor Prodrug.Clin Pharmacokinet, 2014, 53, 385–395.